Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
5.23
-0.53 (-9.20%)
At close: Apr 28, 2026, 4:00 PM EDT
5.32
+0.09 (1.72%)
After-hours: Apr 28, 2026, 7:24 PM EDT
Immuneering Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
53
Market Cap
338.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 316.95K | -1.76M | -84.76% |
| Dec 31, 2021 | 2.08M | -231.57K | -10.02% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| X4 Pharmaceuticals | 35.11M |
| Opus Genetics | 14.20M |
| Armata Pharmaceuticals | 4.90M |
| Surrozen | 3.48M |
| Compass Therapeutics | 850.00K |
| Silence Therapeutics | 559.00K |
| YD Bio | 510.36K |
| Avalo Therapeutics | 59.00K |
IMRX News
- 7 days ago - Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 8 days ago - Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond - GlobeNewsWire
- 15 days ago - Immuneering Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 22 days ago - Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival - GlobeNewsWire
- 7 weeks ago - Immuneering Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - Immuneering to Present at the Leerink Global Healthcare Conference - GlobeNewsWire